https://www.selleckchem.com/pr....oducts/gsk2126458.ht
All affected infants carried the 1330GC (D444H) variant in compound heterozygosis, with variants known to be associated with profound BD. A variant previously not described and likely pathogenic was found in one newborn. None of the infants had signs or symptoms. The study of the distribution of the enzyme activity in our population allowed us to validate the adopted cutoff with which the program has a positive predictive value of 18% and to analyze some preanalytical factors influencing biotinidase activity A correlation of the
Beğen
Yorum Yap
Paylaş
